Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

CNS Oncol. 2015;4(3):131-5. doi: 10.2217/cns.15.3. Epub 2015 Apr 23.


Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

Keywords: CNS lymphoma; indolent lymphoma; intrathecal rituximab; low-grade lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Central Nervous System Neoplasms / cerebrospinal fluid*
  • Central Nervous System Neoplasms / drug therapy*
  • Humans
  • Lymphoma / cerebrospinal fluid*
  • Lymphoma / drug therapy*
  • Male
  • Neoplasm Recurrence, Local
  • Rituximab / therapeutic use*


  • Antineoplastic Agents
  • Rituximab